Expert Review of Anticancer Therapy最新文献_第2页

Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country. 免疫检查点抑制剂对癌症和乙型肝炎患者的安全性和有效性：一个中低收入国家的多中心经验

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-10-01 Epub Date: 2025-07-06 DOI: 10.1080/14737140.2025.2529290

Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman

{"title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country.","authors":"Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman","doi":"10.1080/14737140.2025.2529290","DOIUrl":"10.1080/14737140.2025.2529290","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection.Methods: We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection.Results: Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI.Conclusion: ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1213-1219"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk-reducing surgical timing in BRCA1/2 carriers following breast cancer in the era of PARP inhibitors. PARP抑制剂时代BRCA1/2携带者乳腺癌后手术时机降低风险

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-10-01 Epub Date: 2025-07-17 DOI: 10.1080/14737140.2025.2535656

Yakup Ergun

引用次数: 0

Emerging strategies and advances in the management of sinonasal carcinoma. 鼻窦癌治疗的新策略与进展。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-30 DOI: 10.1080/14737140.2025.2532852

Alicia Tosoni, Maria Pia Foschini, Ernesto Pasquini, Elisa D'Angelo, Vincenzo Di Nunno, Lidia Gatto, Stefania Bartolini, Marta Aprile, Chiara Maria Argento, Marzia Margotti, Giovanni Dima, Enrico Franceschi, Alba Ariela Brandes

{"title":"Emerging strategies and advances in the management of sinonasal carcinoma.","authors":"Alicia Tosoni, Maria Pia Foschini, Ernesto Pasquini, Elisa D'Angelo, Vincenzo Di Nunno, Lidia Gatto, Stefania Bartolini, Marta Aprile, Chiara Maria Argento, Marzia Margotti, Giovanni Dima, Enrico Franceschi, Alba Ariela Brandes","doi":"10.1080/14737140.2025.2532852","DOIUrl":"10.1080/14737140.2025.2532852","url":null,"abstract":"Introduction: Sinonasal tumors are rare and heterogeneous malignancies comprising 3-5% of head and neck cancers, often diagnosed at advanced stages due to nonspecific symptoms and anatomical location. Their proximity to critical structures complicates both surgery and radiotherapy. While multimodal treatment is standard, the role of chemotherapy remains unclear. Advances in molecular profiling have revealed alterations with prognostic and therapeutic relevance, highlighting the need for continued research to enhance treatment strategies. This review is based on all available prospective and retrospective studies, case reports, and review articles published up to May 2025 in PubMed.Areas covered: This article gives an overview of the current knowledge, showing the histological diversity of this area. In this context, we analyze the more recent data on different local treatment options: open and endoscopic surgery, photon and particles bean radiotherapy. We also discuss the role and timing of chemotherapy approaches.Expert opinion: Advances in molecular characterization begin to define new pathological entities that will further improve in future years. Although clinical management of these rare diseases has been improved in recent years, ongoing research investigating the role of chemotherapy in these rare entities is of paramount importance to define appropriate and effective treatment regimens.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1165-1179"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update. 皮肤t细胞淋巴瘤的新非化疗治疗方案——最新进展。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-10-01 Epub Date: 2025-07-09 DOI: 10.1080/14737140.2025.2529289

Tarsheen Sethi, Amrita Goyal-O'Leary, Suzanne Xu, Francine Foss

{"title":"New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update.","authors":"Tarsheen Sethi, Amrita Goyal-O'Leary, Suzanne Xu, Francine Foss","doi":"10.1080/14737140.2025.2529289","DOIUrl":"10.1080/14737140.2025.2529289","url":null,"abstract":"Introduction: Mycosis fungoides (MF) and Sézary syndrome (SS) are T cell lymphomas of the skin with prolonged clinical course requiring multiple lines of therapy in a patient's lifetime. The treatment of MF/SS with available agents is complicated by the differential response in skin, lymph nodes, and blood. Advances in understanding the biology of the disease have led to therapies with better efficacy and improvement in quality of life for patients with relapsed and refractory disease.Areas covered: This review will outline clinical data for novel biologics including monoclonal antibodies, small molecule inhibitors, and immunotherapeutic approaches such as CAR-T and bispecific antibodies.Expert opinion: Nonchemotherapy options which avoid generalized immunosuppression are a preferred consideration for patients with MF/SS, given the compromised skin integument of these patients. Targeted therapies including brentuximab vedotin, lacutamab, denileukin diftitox, and mogamulizumab have shown activity in registrational trials. Novel agents which modulate tumor microenvironment and upregulate tumor-specific immune responses have been in clinical trials, including bispecific antibodies recruiting immune effectors, agents eradicating suppressive microenvironments, and engineered T cells targeting tumor epitopes. Checkpoint inhibitors may play a role in MF/SS but their role has not been well defined, and they may induce hyper progression.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1141-1152"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer - implications for daily clinical practice. 一线免疫检查点抑制剂在PD-L1 < 1%转移性非小细胞肺癌患者中的疗效和安全性——对日常临床实践的意义

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-22 DOI: 10.1080/14737140.2025.2557610

Maciej Bryl, Katarzyna Stencel, Magdalena Knetki-Wróblewska, Maciej Krzakowski

{"title":"Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer - implications for daily clinical practice.","authors":"Maciej Bryl, Katarzyna Stencel, Magdalena Knetki-Wróblewska, Maciej Krzakowski","doi":"10.1080/14737140.2025.2557610","DOIUrl":"10.1080/14737140.2025.2557610","url":null,"abstract":"Introduction: Patients with advanced/metastatic non-small cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) tumor cell expression <1% are difficult to treat, and an optimal treatment strategy for these patients is yet to be defined.Areas covered: There have been significant advances in immunotherapy for NSCLC in the past decade. This article aims to answer the question of the optimal first-line treatment for patients with advanced/metastatic NSCLC and PD-L1 expression <1%, based on efficacy and safety data from phase 3 studies (published up to 31 December 2024).Expert opinion: Current evidence from subgroup and exploratory analyses of phase 3 studies and indirect comparisons suggest that PD-1/PD-L1 inhibitors (with or without chemotherapy) combined with a cytotoxic T lymphocyte-associated protein-4 inhibitor or antiangiogenic therapy may provide the highest progression-free survival (PFS) and overall survival (OS) benefits in patients with newly diagnosed advanced/metastatic NSCLC and PD-L1 tumor cell expression <1%. Of these regimens, dual immunotherapy with nivolumab and ipilimumab combined with chemotherapy appeared to offer some advantages in terms of OS, PFS, objective response rates, and duration of response, relative to other treatment approaches. Well-designed, comparative studies are warranted to more definitively determine the best first-line treatment for these patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-21"},"PeriodicalIF":2.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes. 帕博西尼治疗内分泌耐药转移性乳腺癌：现实世界的结果。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-21 DOI: 10.1080/14737140.2025.2560941

Abdel-Hameed Ibrahim Mohamed Ebid, Yasmine Magdy Fahim Genina, Hesham Raafat Shawky Haffez, Sherif Hassanien Ahmed Hakam, Loay Mohamed Hassan Kassem, Sara Mohamed Mohamed AbdelMotaleb

{"title":"Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.","authors":"Abdel-Hameed Ibrahim Mohamed Ebid, Yasmine Magdy Fahim Genina, Hesham Raafat Shawky Haffez, Sherif Hassanien Ahmed Hakam, Loay Mohamed Hassan Kassem, Sara Mohamed Mohamed AbdelMotaleb","doi":"10.1080/14737140.2025.2560941","DOIUrl":"10.1080/14737140.2025.2560941","url":null,"abstract":"Background: Palbociclib is a cornerstone treatment for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer.Research design and methods: This retrospective cohort study included 140 patients who were resistant to endocrine therapy and received palbociclib in combination with endocrine therapy. It is aimed to evaluate the efficacy and tolerability of palbociclib and to identify factors influencing progression-free survival and overall survival.Results: A total of 140 were enrolled in the study; 57 and 83 patients were primary and secondary resistance to endocrine therapy, respectively. In the whole cohort, regarding progression-free survival; low Ki-67 and incidence of moderate-to-severe (grade 3/4) neutropenia were associated with longer median progression-free survival with p-values of 0.004 (3.7 vs. 8.4 months) and 0.026 (4.7 vs. 6.5 months), respectively. Regarding overall survival, duration on palbociclib (≥12 months) had longer overall survival compared with patients who received palbociclib <12 months (p = 0.0012). The overall survival was longer in the secondary-resistant group than in the primary-resistant group (log-rank test p = 0.0003).Conclusion: In a metastatic setting, low Ki-67 and moderate-to-severe neutropenia are associated with better survival outcomes in endocrine resistant patients treated with palbociclib (Clinical trial registration: www.clinicaltrials.gov identifier is NCT06338644).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward clinical translation of AI-Led drug discovery in endometrial cancer. 人工智能在子宫内膜癌药物发现中的临床应用。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-15 DOI: 10.1080/14737140.2025.2557602

Phat Ky Nguyen, Thi-My-Trang Luong, Xuan Lam Bui, Nguyen Quoc Khanh Le

{"title":"Toward clinical translation of AI-Led drug discovery in endometrial cancer.","authors":"Phat Ky Nguyen, Thi-My-Trang Luong, Xuan Lam Bui, Nguyen Quoc Khanh Le","doi":"10.1080/14737140.2025.2557602","DOIUrl":"10.1080/14737140.2025.2557602","url":null,"abstract":"Introduction: Deep learning (DL) is transforming cancer research by enabling data-driven drug discovery. However, its clinical translation, particularly in endometrial cancer (EC), faces significant challenges.Areas covered: This review discusses recent DL applications across drug discovery stages in EC, including target identification, virtual screening, and de novo drug design. We highlight key obstacles that hinder clinical translation, such as data scarcity, limited model explainability, biological validation gaps, and regulatory uncertainty, and propose practical solutions. Literature was sourced from PubMed, Web of Science, and relevant AI repositories, with an emphasis on peer-reviewed studies from the past five years.Expert opinion: Despite early success, DL must overcome multiple translational bottlenecks to impact EC therapeutics meaningfully. A multidisciplinary approach that incorporates data quality improvements, functional validation, regulatory engagement, and clinician-focused decision support is essential to fully realize the clinical promise of DL-driven drug discovery in EC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-20"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epstein-Barr virus (EBV) infection and associated post transplantation lymphoproliferative disease (PTLD) in hematopoietic stem cell transplantation (HSCT): a prevalence based systematic review and meta-analysis on global epidemiology. Epstein-Barr病毒（EBV）在造血干细胞移植（HSCT）中相关的移植后淋巴细胞增生性疾病（PTLD）：一项基于流行率的全球流行病学系统综述和荟萃分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-08 DOI: 10.1080/14737140.2025.2557615

Awais Mustafa, Shahad Saif Khandker, Umme Farwa, Muhammad Hamza Saeed, Muhammad Sarfraz, Abdul Manan, Hifza Ishtiaq Gillani, Amna Akbar, Khawaja Faizan Ejaz, Asma Atta, Maryam Atta, Alif Hasan Pranto, Brian Gomes, Anikah Lubaba, Thamjeed Mohaimeen, Shifaty Nur Abir, Mohammad Saleem Khan

{"title":"Epstein-Barr virus (EBV) infection and associated post transplantation lymphoproliferative disease (PTLD) in hematopoietic stem cell transplantation (HSCT): a prevalence based systematic review and meta-analysis on global epidemiology.","authors":"Awais Mustafa, Shahad Saif Khandker, Umme Farwa, Muhammad Hamza Saeed, Muhammad Sarfraz, Abdul Manan, Hifza Ishtiaq Gillani, Amna Akbar, Khawaja Faizan Ejaz, Asma Atta, Maryam Atta, Alif Hasan Pranto, Brian Gomes, Anikah Lubaba, Thamjeed Mohaimeen, Shifaty Nur Abir, Mohammad Saleem Khan","doi":"10.1080/14737140.2025.2557615","DOIUrl":"10.1080/14737140.2025.2557615","url":null,"abstract":"Introduction: Hematopoietic stem cell transplantation (HSCT) is a widely used transplant method for different cancerous and non-cancerous conditions, particularly when conventional treatments fail. Again, Epstein-Barr Virus (EBV), one of the major contributors to gastric carcinoma can cause post-transplantation lymphoproliferative disease (PTLD) after transplantations. However, the global prevalence of EBV infection and associated PTLD in HSCT recipients is yet to be determined.Methods: This research examined 33 studies selected from 941 articles across three databases (i.e. ScienceDirect, PubMed, and Google Scholar) to investigate the global epidemiology of EBV infection and associated PTLD in HSCT patients.Results: The overall prevalence was calculated primarily as 27.0%; 95% CI: 24.5-29.5, and 23.7%; 95% CI: 19.3-28.3 after removing outlier studies. The analyzed studies were of high quality. Among different continents, North America was determined to have the highest prevalence rate (33.3%; 95%CI: 12.5-54.1) followed by Europe (27.8%; 95%CI: 23.3-32.2), and Asia (20.7%; 95%CI: 17.4-23.9).Conclusion: This investigation highlights the need for early detection of EBV infection and associated PTLD, personalized treatment strategies, and continued research into the condition's underlying mechanisms. Addressing these aspects can enhance outcomes for HSCT patients and contribute to advancements in transplant medicine.Registration: PROSPERO (CRD420250583221).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Importance of radiation-related cognitive decline in older adults who receive cranial radiation. 接受颅辐射的老年人与辐射相关的认知能力下降的重要性。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-07 DOI: 10.1080/14737140.2025.2555472

Felicia H Lew, Karl Cristie Figuracion, Shannon E Fogh, David P Sheppard, Yolanda D Tseng, Lia M Halasz, Jerome J Graber, Samuel Emerson, Simon S Lo, Sara J Hardy

{"title":"Importance of radiation-related cognitive decline in older adults who receive cranial radiation.","authors":"Felicia H Lew, Karl Cristie Figuracion, Shannon E Fogh, David P Sheppard, Yolanda D Tseng, Lia M Halasz, Jerome J Graber, Samuel Emerson, Simon S Lo, Sara J Hardy","doi":"10.1080/14737140.2025.2555472","DOIUrl":"10.1080/14737140.2025.2555472","url":null,"abstract":"Introduction: Radiation-related cognitive decline (RRCD), characterized by a decline in cognitive functioning within domains, such as memory and executive function, is a known potential consequence of cranial radiation. Older adults are disproportionately vulnerable to cognitive side effects of radiation (RT), and there can be significant impacts on quality of life and independence. Various mechanisms underlying the development of RRCD have been proposed but have not been specifically evaluated in older adults.Areas covered: In this article, we review the studies that have evaluated cognitive effects of cranial radiation in older adults and discuss the mechanisms and factors that may lead to increased vulnerability of RRCD development in older adults.Expert opinion: The review of the literature is limited by the variety of cognitive outcome measurements used as well as different ages evaluated. However, most studies support increased vulnerability to RRCD in older adults. No studies include geriatric assessment or other measures of biological age. Potential interventions include redefining whether different dose constraints are warranted in the older adult population, evaluating new medication interventions and utilizing radiation techniques that treat smaller volumes. Further research is needed to determine whether there is a corresponding reduction in RRCD.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.8,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden trends and risk factors for prostate cancer from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021. 1990年至2021年前列腺癌负担趋势和危险因素：对2021年全球疾病负担研究的系统分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-03 DOI: 10.1080/14737140.2025.2555466

Yuan Xu, Ruilin Li, Ning Wang, Yan Guo, Chang Wang, Qinduo Ren, Songlin Lu, Shuo Bi, Hongsheng Tian, Xuying Guo, Yuping Zou, Linna Yuan, Wei She, Hongmei Sun, Yu Dong, Chen Zhang, Ye Ma, Zhenwei Shang, Yongshuai Jiang, Wenhua Lv, Hongchao Lv, Mingming Zhang

{"title":"Burden trends and risk factors for prostate cancer from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.","authors":"Yuan Xu, Ruilin Li, Ning Wang, Yan Guo, Chang Wang, Qinduo Ren, Songlin Lu, Shuo Bi, Hongsheng Tian, Xuying Guo, Yuping Zou, Linna Yuan, Wei She, Hongmei Sun, Yu Dong, Chen Zhang, Ye Ma, Zhenwei Shang, Yongshuai Jiang, Wenhua Lv, Hongchao Lv, Mingming Zhang","doi":"10.1080/14737140.2025.2555466","DOIUrl":"https://doi.org/10.1080/14737140.2025.2555466","url":null,"abstract":"Objectives: Prostate cancer (PCa) is one of the most common malignancies in males worldwide. Therefore, conducting the latest and comprehensive assessment of PCa is important.Research design and methods: Average annual percent change for age-standardized rate trend was calculated by Joinpoint. Pearson correlation analyzed the relationship between PCa and Sociodemographic Index (SDI). Causal associations of risk factors were examined by two-sample mendelian randomization. Bayesian age-period-cohort model was used to predict incidence trends to 2050.Results: In 2021, the global incidence of PCa was 1,324,383, an increase of 161.53% since 1990. It was mainly concentrated in the age group of 65-79. From 1990 to 2021, the global incidence and prevalence increased slightly. PCa was more common in regions with a high SDI. Mortality was the highest in regions with a low SDI. Smoking and telomere length were found to be risk factors for PCa, and diet low in calcium and milk was also related to PCa. The prediction results revealed that the incidence of PCa will slightly decrease in the future.Conclusions: The disease burden of PCa gradually increased from 1990 to 2021. There were significant differences across countries, SDI regions, and age groups. By 2050, the incidence of this disease is expected to decrease.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0